ArticleClinical and translational radiation oncology2025
Patient-reported outcomes between proton and photon therapy in nasopharyngeal carcinoma patients: A longitudinal cohort study.
Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Otolaryngologic Symptom Burden, Emotional Distress, and Stigma in Nasopharyngeal Carcinoma Survivors: A Prospective Cohort Study.Psycho-oncology · 2026Observational
- Validating cancer-specific and generic quality of life (QoL) instruments among patients with head and neck cancers: incorporating the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck Module with generic QoL instruments.Psicologia, reflexao e critica : revista semestral do Departamento de Psicologia da UFRGS · 2026Article
- Determinants of long-term quality of life in nasopharyngeal carcinoma survivors: the roles of household income and performance status.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: This study aimed to compare patient-reported outcomes (PROs) between intensity-modulated proton therapy (IMPT) and volumetric-modulated arc therapy (VMAT) in treating nasopharyngeal carcinoma (NPC). Materials and methods: A prospective cohort study was conducted at a tertiary care center from 2021 to 2023. Newly diagnosed NPC patients were assessed using the modified 28-item symptom distress scale at seven time points, from baseline (T0) to one year post-radiotherapy (RT) (T6). The analysis focused on symptom changes during the acute phase (T0 to T3 [one month post-RT]) using linear mixed models. Sensitivity analyses incorporated inverse probability treatment weighting and data from non-metastatic patients adhering to survey protocols. Results: IMPT recipients (n = 65) had higher education levels, marital stability, household incomes, and better performance statuses compared to VMAT recipients (n = 36). Oral-related symptoms peaked by the seventh week of RT and declined thereafter. IMPT significantly reduced "oral ulcer" (coefficient: -0.83, SE: 0.27) and "difficulty opening mouth" (coefficient: -0.44, SE: 0.18) symptoms by the seventh week but did not improve "dry mouth." "Tinnitus" was rated as more distressing than "hearing difficulty," with no significant differences between IMPT and VMAT for ear-related symptoms. Sensitivity analyses validated these findings. Conclusion: IMPT was associated with reduced severity of specific oral-related symptoms during the acute phase of RT compared to VMAT. While these findings suggest potential benefits of IMPT, baseline differences between groups necessitate cautious interpretation and further validation through randomized studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.